Pharmaceutical Business review is using cookies

ContinueLearn More
December 11, 2018

BMS, Vedanta Biosciences to evaluate Opdivo-VE800 combo in metastatic cancers

Bristol-Myers Squibb will evaluate Opdivo (nivolumab) in combination with Vedanta Biosciences’ VE800, a live biotherapeutic product (LBP), in patients with advanced or metastatic cancers.

Image: BMS enters into clinical collaboration with Vedanta Biosciences. Photo: courtesy of Sue Adair/